Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Autolus Therapeutics plc

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

AUTOLUS PRESENTED PRELIMINARY DATA FROM THE PHASE 1 CARLYSLE TRIAL IN PATIENTS WITH SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (SRSLE) AT ASH 2025.

AUTOLUS THERAPEUTICS PRESENTS UPDATED CLINICAL DATA FROM THE CARLYSLE TRIAL IN PATIENTS WITH SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2025

OBE-CEL DEMONSTRATES HIGH REMISSION RATES IN PEDIATRIC PATIENTS WITH HIGH-RISK R/R B-ALL WITH OVERALL RESPONSE RATE (ORR) OF 95.5%; LOW RATES OF HIGH-GRADE CYTOKINE RELEASE SYNDROME (CRS) AND IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) OBSERVED, CONSISTENT WITH OBE-CEL'S ADULT SAFETY PROFILE FELIX STUDY DATA ANALYSES HIGHLIGHT PRODUCT CELL PHENOTYPE AND LEVEL OF CAR T PERSISTENCE AT THREE MONTHS AS POTENTIAL PREDICTORS OF LONG-TERM REMISSION REAL-WORLD DATA INDEPENDENTLY COLLECTED BY THE ROCCA CONSORTIUM DURING THE US COMMERCIAL LAUNCH OF OBE-CEL WERE PRESENTED AND SHOW A HIGH RESPONSE RATE AND LOW LEVELS OF HIGH-GRADE CRS AND ICANS CONSISTENT WITH THE CLINICAL TRIAL EXPERIENCE IN THE FELIX STUDY LONDON AND GAITHERSBURG, MD., DEC. 08, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, ANNOUNCES PRESENTATION OF PRELIMINARY DATA FROM THE CATULUS PHASE 1 TRIAL OF OBE-CEL IN PEDIATRIC RELAPSED OR REFRACTORY (R/R) B-ALL PATIENTS, AS WELL AS FURTHER INSIGHTS FROM THE REGISTRATIONAL FELIX STUDY IN ADULT R/R B-ALL, AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING.

AUTOLUS THERAPEUTICS PRESENTS INITIAL CLINICAL DATA IN PEDIATRIC R/R B-ALL PATIENTS AND OTHER ONCOLOGY DATA AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2025

LONDON AND GAITHERSBURG, MD., DEC. 01, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), AN EARLY COMMERCIAL STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, TODAY ANNOUNCED THE APPOINTMENT OF RYAN RICHARDSON TO THE COMPANY'S BOARD OF DIRECTORS.

AUTOLUS THERAPEUTICS APPOINTS RYAN RICHARDSON TO BOARD OF DIRECTORS

LONDON, NOV. 25, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, ANNOUNCES THAT THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) HAS PUBLISHED DRAFT GUIDANCE1 RECOMMENDING AUCATZYL (OBECABTAGENE AUTOLEUCEL, OR OBE-CEL)2 FOR USE IN THE NATIONAL HEALTH SERVICE (NHS) INENGLAND AND WALES AS A TREATMENT OPTION FOR ADULT PATIENTS (26 YEARS) WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL). AUCATZYL WILL BE AVAILABLE THROUGH ROUTINE COMMISSIONING BY THE NHS.

NICE RECOMMENDS AUCATZYL (OBECABTAGENE AUTOLEUCEL) AS A TREATMENT OPTION FOR ADULT PATIENTS (26 YEARS) WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL)

LONDON AND GAITHERSBURG, MD., NOV. 13, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, ANNOUNCES THAT THE COMPANY WILL PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON.

AUTOLUS THERAPEUTICS TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON

COMPANY REPORTS Q3 2025 AUCATZYL NET PRODUCT REVENUE OF $21.1 MILLION AND DEFERRED REVENUE OF $7.6 MILLION; 60 AUTHORIZED TREATMENT CENTERS ACHIEVED AHEAD OF TARGET CLINICAL EXECUTION AND DATA GENERATION TO SUPPORT MARKET GROWTH AND EXPANSION CONTINUES; DATA IN SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (SRSLE) SHOW NO ICANS OR HIGH-GRADE CRS, DEMONSTRATE ACHIEVEMENT OF DEFINITION OF REMISSION IN SLE (DORIS) IN 83% (N=5/6) OF PATIENTS AND COMPLETE RENAL RESPONSE (CRR) IN 50% (N=3/6) OF PATIENTS LEADERSHIP TEAM BOLSTERED TO SUPPORT NEXT PHASE OF GROWTH AND OPTIMIZATION OF BUSINESS OPERATIONS CONFERENCE CALL TO BE HELD TODAY AT 8:30 AM EST / 1:30 PM GMT; CONFERENCE CALL PARTICIPANTS SHOULD PRE-REGISTER USING THE LINK AT THE BOTTOM OF THIS PRESS RELEASE LONDON AND GAITHERSBURG, MD., NOV. 12, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, ANNOUNCES ITS OPERATIONAL AND FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025.

AUTOLUS THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

LONDON AND GAITHERSBURG, MD., NOV. 03, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, ANNOUNCES THE ONLINE PUBLICATION OF FIVE ABSTRACTS SUBMITTED TO THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING, TO BE HELD DECEMBER 6-9, 2025, IN ORLANDO, FLORIDA.

AUTOLUS THERAPEUTICS TO PRESENT CLINICAL DATA UPDATES AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2025

LONDON & GAITHERSBURG, MD., OCT. 30, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, TODAY ANNOUNCES THAT IT WILL RELEASE ITS THIRD QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS BEFORE OPEN OF U.S. MARKETS ON WEDNESDAY, NOVEMBER 12, 2025.

AUTOLUS THERAPEUTICS TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON NOVEMBER 12, 2025

DATA FROM THE PHASE 1 CARLYSLE STUDY IN SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (SRSLE) SUGGESTS OBE-CEL IS WELL TOLERATED WITH NO ICANS OR HIGH-GRADE CRS; 50 MILLION CELL DOSE SELECTED FOR PHASE 2 PIVOTAL STUDY PRELIMINARY EFFICACY DATA DEMONSTRATE ACHIEVEMENT OF DEFINITION OF REMISSION IN SLE (DORIS) IN 83% OF PATIENTS AND COMPLETE RENAL RESPONSE (CRR) IN 50% OF PATIENTS; ALL RESPONSES AND REMISSIONS ARE ONGOING WITH NO EVIDENCE OF DISEASE ACTIVITY AT A MEDIAN FOLLOW-UP OF 8.9 MONTHS ALL PATIENTS HAD REFRACTORY LUPUS NEPHRITIS; 4/6 PATIENTS HAD SIGNIFICANTLY IMPAIRED KIDNEY FUNCTION PATIENTS RECEIVED NO OTHER LUPUS DIRECTED THERAPY; STEROIDS WERE TAPERED IN ALL PATIENTS TO 5MG BY MONTH SIX COMPANY REMAINS ON TRACK TO DOSE FIRST PATIENT IN PHASE 2 TRIAL IN LUPUS NEPHRITIS (LN) BY YEAR-END 2025 LONDON AND GAITHERSBURG, MD., OCT. 27, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, ANNOUNCES THAT FOLLOW-UP DATA FROM THE ONGOING CARLYSLE TRIAL, A PHASE 1 DOSE CONFIRMATION CLINICAL TRIAL OF OBE-CEL IN SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (SRSLE), WILL BE PRESENTED DURING A POSTER SESSION AT THE AMERICAN COLLEGE OF RHEUMATOLOGY CONVERGENCE 2025.

AUTOLUS THERAPEUTICS PRESENTS CLINICAL DATA UPDATES AT THE AMERICAN COLLEGE OF RHEUMATOLOGY CONVERGENCE 2025

LONDON AND GAITHERSBURG, MD., OCT. 20, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, ANNOUNCES THAT THE FIRST PATIENT HAS BEEN DOSED IN ITS PHASE 1 BOBCAT TRIAL OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS (PMS).

AUTOLUS THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 TRIAL OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS

Autolus Therapeutics plc

AUTL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Autolus Therapeutics plc

AUTL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AUTL